STOCK TITAN
  1. Home
  2. News
  3. PDSB

PDS Biotechnology Corporation - PDSB STOCK NEWS

Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.

PDS Biotechnology Corporation (Nasdaq: PDSB) is a clinical stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and infectious diseases. The company's proprietary Versamune® platform leverages synthetic and biodegradable lipids to form nanoparticles that are readily taken up by the immune system. These nanoparticles are designed to activate and direct the immune system to target and eliminate disease-causing cells.

PDS Biotech's lead product candidates include PDS0101, targeting HPV-related cancers, and PDS01ADC, an IL-12 fused antibody drug conjugate. These candidates are part of the company's broader strategy to treat a range of cancers, including head and neck, prostate, breast, cervical, and anal cancers.

Recent achievements include the completion of a Phase 1 clinical trial for PDS0101 and ongoing Phase 2 trials demonstrating positive survival results and tumor shrinkage. The company is preparing to initiate a pivotal clinical trial in advanced head and neck cancers in 2024.

Financially, PDS Biotech reported a net loss of $10.8 million for Q3 2023, primarily due to increased R&D and administrative expenses. Despite this, the company remains focused on advancing its pipeline and has several key partnerships to support its research and development efforts.

News

PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023

Rhea-AI Summary
PDS Biotech to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA® in a KOL Roundtable event on September 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
News

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
PDS Biotech to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
-
News

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

Rhea-AI Summary
PDS Biotech to present data on PDS0202 universal influenza vaccine at ESWI Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
News

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting

Rhea-AI Summary
PDS Biotech announced that data from the IMMUNOCERV Phase 2 clinical trial investigating PDS0101 in combination with standard-of-care chemoradiotherapy for the treatment of cervical cancer will be presented at the ASTRO 2023 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
clinical trial
-
News

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
PDS Biotech submits final clinical protocol for Phase 3 trial, presents biomarker data at ESMO 2023, and discusses financial results. Lead drug candidate shows promising results in Phase 2 trial. Antibody-conjugated IL-12 to be presented at Cytokines 2023. Net loss for Q2 2023 increased due to R&D expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.9%
Tags
earnings
-
News

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the submission to the FDA of an updated CMC package and a Phase 3 multicenter registrational protocol to evaluate the combination of PDS0101 and KEYTRUDA® for the treatment of recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma. The Phase 3 trial, named VERSATILE-003, is a randomized, active comparator-controlled study designed to investigate the safety and efficacy of PDS0101 combined with KEYTRUDA® compared to KEYTRUDA® monotherapy in immune checkpoint inhibitor (ICI)-naïve patients with recurrent or metastatic HPV16-positive HNSCC. PDS Biotech anticipates initiating the VERSATILE-003 Phase 3 trial in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.9%
Tags
clinical trial
News

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

Rhea-AI Summary
PDS Biotechnology Corporation will release its financial results for Q2 2023 on August 14, 2023, before the market opens. The company is a clinical-stage immunotherapy company developing targeted cancer immunotherapies and infectious disease vaccines. A conference call will be held to review the financial results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
-
News

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
conferences
-
News

PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
News

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

Rhea-AI Summary
PDS Biotechnology announces interim data from a clinical trial combining PDS0301 immunocytokine with docetaxel in prostate cancer patients. The trial is investigating the safety, immune responses, and clinical activity of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
none

FAQ

What is the current stock price of PDS Biotechnology Corporation (PDSB)?

The current stock price of PDS Biotechnology Corporation (PDSB) is $2.2 as of November 21, 2024.

What is the market cap of PDS Biotechnology Corporation (PDSB)?

The market cap of PDS Biotechnology Corporation (PDSB) is approximately 75.4M.

What is PDS Biotechnology Corporation's main area of focus?

PDS Biotechnology focuses on developing next-generation immunotherapies for cancer and infectious diseases using its proprietary Versamune® platform.

What is the Versamune® platform?

The Versamune® platform uses synthetic and biodegradable lipids to form nanoparticles that activate and direct the immune system to target disease-causing cells.

Which cancers are targeted by PDS Biotechnology's therapies?

PDS Biotechnology's therapies target various cancers including head and neck, prostate, breast, cervical, and anal cancers.

What are the recent achievements of PDS Biotechnology?

Recent achievements include completing a Phase 1 clinical trial for PDS0101 and ongoing successful Phase 2 trials showing positive results.

How did PDS Biotechnology perform financially in Q3 2023?

PDS Biotechnology reported a net loss of $10.8 million for Q3 2023, mainly due to higher research and development and administrative expenses.

What is PDS01ADC?

PDS01ADC is an IL-12 fused antibody drug conjugate in development for use in PDS Biotechnology's cancer immunotherapy treatments.

What upcoming events should investors watch?

Investors should watch for the pivotal clinical trial in advanced head and neck cancers planned for 2024.

What are the unique features of PDS Biotechnology's vaccines?

PDS Biotechnology's vaccines induce robust neutralizing antibodies and powerful T-cell responses, including long-lasting memory T-cells.

Where can investors find more information about PDS Biotechnology?

Investors can find more information on the company's official website at www.pdsbiotech.com.

How can the media contact PDS Biotechnology?

Media can contact PDS Biotechnology through Gina Mangiaracina at 6 Degrees via phone at +1 (917) 797-7904 or email at gmangiaracina@6degreespr.com.

Stock PDSB logo
PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

#4581 Ranked by Market Cap
N/A Ranked by Dividends

PDSB Stock Data

75.38M
36.02M
3.99%
12.36%
12.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON